<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803788</url>
  </required_header>
  <id_info>
    <org_study_id>202/GMC/IEC/04/2014</org_study_id>
    <nct_id>NCT02803788</nct_id>
  </id_info>
  <brief_title>Post-operative Nausea Vomiting in Laparoscopic Cholecystectomy</brief_title>
  <acronym>PONV</acronym>
  <official_title>Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Government Medical College, Haldwani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Government Medical College, Haldwani</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To study the efficacy and side effects of ondansetron with dexamethasone in patients&#xD;
           undergoing standard laparoscopic cholecystectomy (control group).&#xD;
&#xD;
        -  To study the efficacy and side effects of ramosetron in patients undergoing standard&#xD;
           laparoscopic cholecystectomy (study group).&#xD;
&#xD;
        -  To compare the efficacy and side effects of ondansetron with dexamethasone and&#xD;
           ramosetron in patients undergoing standard laparoscopic cholecystectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 ASA Grade I/II young female patients of 20-40 years undergoing elective laparoscopic&#xD;
      cholecystectomy will be equally divided into 2 groups (50 each): control group(Group 'O') and&#xD;
      study group (Group 'R') using a computer generated sealed envelopes.&#xD;
&#xD;
      Control group patients will receive ondansetron with dexamethasone and the study group&#xD;
      patients will receive ramosetron. Based on the previous studies advocating use of the minimum&#xD;
      recommended doses, ramosetron in a dose of 0.3 mg and ondansetron in a dose of 4 mg and&#xD;
      dexamethasone in a dose of 8mg will be administered for prevention of PONV in the present&#xD;
      study. Medications will be prepared by a blinded paramedic not involved in the study in&#xD;
      identical 5-ml syringes and will be administered according to the randomization list.&#xD;
      Patients will be given tablet alprazolam(0.25 mg) orally on the night before surgery and&#xD;
      advised nil per orally from midnight.&#xD;
&#xD;
      Inside operation theatre, patient NPO status and identity will be reassured. Intravenous line&#xD;
      will be secured using 18 G IV cannula and intravenous fluid will be started. Standard&#xD;
      non-invasive monitoring will be established intraoperatively using NIBP, HR, ECG, RR, SpO2&#xD;
      and will be continuous postoperatively. Patients will be premedicated with injection&#xD;
      Glycopyrrolate (0.004mg/kg), injection Ranitidine (1mg/kg), injection metoclopramide&#xD;
      (0.15mg/kg), injection butorphanol (0.04mg/kg). Patients will be induced with injection&#xD;
      propofol 2 mg/ kg mixed with xylocard 2%(10mg of xylocard per 10ml propofol) and injection&#xD;
      Succinylcholine 1.5 mg/kg and endotracheal intubation will be done. A nasogastric tube will&#xD;
      be inserted after securing the endotracheal tube in place and confirming it with ETCO2&#xD;
      monitoring. Anesthesia will be maintained with nitrous oxide and halothane (0.4-1%) in&#xD;
      oxygen. Intra-operative muscle relaxation was maintained with injection vecuronium.&#xD;
&#xD;
      At the end of the surgery, injection diclofenac 75 mg IM will be given before the reversal of&#xD;
      neuromuscular blockade to pre-empt the post-operative pain and will be advised as IM&#xD;
      injection twice a day for post operative analgesia. Additional post-operative analgesia will&#xD;
      be provided with injection tramadol 2 mg/ kg slowly as and when required intravenously.&#xD;
      Nasogastric suction will be done to remove any residual gastric contents. Residual effect of&#xD;
      muscle relaxant will be reversed with injection neostigmine (0.04 mg/ kg) and injection&#xD;
      glycopyrrolate (0.2mg for each 1.0 mg 0f neostigmine). Ondansetron (4 mg) with dexamethasone&#xD;
      (8mg) or ramosetron (0.3 mg) will be administered intravenously before shifting of the&#xD;
      patient from the operation theater to the post-anesthesia care unit (PACU) according to the&#xD;
      group allocation. All port sites will be infiltrated with inj bupivacaine (0.25%).&#xD;
&#xD;
      In the post-operative period, patients will be monitored for nausea, vomiting, pain, vital&#xD;
      signs, adverse effects and post-anesthetic discharge score for 48 h (every 4 hourly in first&#xD;
      24 hours and every 6 hourly in next 24 hours) and this will be recorded by an independent&#xD;
      observer (usually a Resident Officer) who will be blinded to the study. Injection&#xD;
      metoclopramide (10 mg I.V.) will be administered as an additional rescue antiemetic in&#xD;
      patients with two or more than two episodes of vomiting and/or significant nausea at any time&#xD;
      within 48 h of operation. Exact timing of the administration of the rescue antiemetic will be&#xD;
      recorded.&#xD;
&#xD;
      Adverse effects of Ramosetron will also be monitored like- Abdominal pain, Hard stools,&#xD;
      Constipation, bloating, Hepatic dysfunction, reflux esophagitis, decrease in platelet count,&#xD;
      Duodenal ulcer, Palpitation.&#xD;
&#xD;
      Nausea is defined as a subjectively unpleasant sensation associated with awareness of the&#xD;
      urge to vomit whereas retching is defined as the labored spasmodic, rhythmic contraction of&#xD;
      the abdominal muscles without expulsion of gastric contents, and vomiting is defined as the&#xD;
      forceful expulsion of gastric contents from the mouth. Nausea will be measured using an 10&#xD;
      point numerical visual analogue scale with 0 = no nausea and 10 = nausea as bad as can be. A&#xD;
      score of &gt; 5 will be considered severe, 5 = moderate and &lt; 5 = minimal. The moderate and&#xD;
      severe nausea will be considered as major nausea. During the period of monitoring, the&#xD;
      -vomiting/retching episodes of &gt;2 will be considered severe, 2 as moderate, and &lt;2 as mild.&#xD;
      Vomiting occurring up to 24 h after surgery will be taken as early vomiting whereas delayed&#xD;
      vomiting consist of vomiting occurring during 24-48 h after surgery. A complete response will&#xD;
      be defined as the absence of PONV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of antiemetic effect of Ramosetron with combination of Ondansetron and Dexamethasone in patients undergoing laparoscopic cholecystectomy</measure>
    <time_frame>0-48 hrs post-operative period</time_frame>
    <description>patients will be monitored for vitals, nausea, vomiting, any adverse effect of drug and pain in post-operative period upto 48hrs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Group O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this group will receive inj. ondansetron 4mg iv stat and inj. dexamethasone 8mg iv stat just before extubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this group will receive inj. ramosetron 0.3mg iv stat just before extubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron, ondansetron, dexamethasone</intervention_name>
    <description>prevention of post-operative nausea vomiting</description>
    <arm_group_label>Group O</arm_group_label>
    <arm_group_label>Group R</arm_group_label>
    <other_name>anti-emetics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients of age group 20 - 40years undergoing elective laparoscopic&#xD;
             cholecystectomy&#xD;
&#xD;
          -  ASA Physical Status- I &amp; II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Negative consent&#xD;
&#xD;
               -  History of motion sickness&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Menstruating females&#xD;
&#xD;
               -  Antiemetic taken within 24 hours before surgery or any long term medication&#xD;
&#xD;
               -  History of any systemic diseases, cardio- respiratory, hepato-renal,&#xD;
                  neurological, endocrinal disorders, hematological disorders, drug or alcohol&#xD;
                  addiction, psychiatric diseases, study drug sensitivity, etc&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>C P Bhaisora, MD</last_name>
    <phone>05946228393</phone>
    <email>principal.gmchld@rediffmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A K Pandey, MD</last_name>
    <phone>05946235444</phone>
    <email>telemedgmchld@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GMC Haldwani</name>
      <address>
        <city>Haldwani</city>
        <state>Uttarakhand, India</state>
        <zip>263139</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shagufta Ansari, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Urmila Palaria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajay K Sinha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bikramjit Das, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Government Medical College, Haldwani</investigator_affiliation>
    <investigator_full_name>Dr Shagufta Ansari</investigator_full_name>
    <investigator_title>COMPARATIVE STUDY OF ANTIEMETIC EFFECT OF RAMOSETRON WITH COMBINATION OF ONDANSETRON AND DEXAMETHASONE IN PATIENT UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY</investigator_title>
  </responsible_party>
  <keyword>ramosetron, ondansetron, dexamethasone,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 10, 2017</submitted>
    <returned>June 23, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

